These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22879738)

  • 1. Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation.
    Matza LS; Phillips GA; Revicki DA; Ascher-Svanum H; Malley KG; Palsgrove AC; Faries DE; Stauffer V; Kinon BJ; Awad AG; Keefe RS; Naber D
    Patient Prefer Adherence; 2012; 6():521-32. PubMed ID: 22879738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia.
    Matza LS; Phillips GA; Revicki DA; Ascher-Svanum H; Malley KG; Palsgrove AC; Faries DE; Stauffer V; Kinon BJ; George Awad A; Keefe RS; Naber D
    Psychiatry Res; 2012 Dec; 200(2-3):835-42. PubMed ID: 22841345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.
    Faries D; Ascher-Svanum H; Phillips G; Nyhuis AW; Sugihara T; Stauffer V; Kinon BJ
    BMC Med Res Methodol; 2012 Sep; 12():142. PubMed ID: 22974273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.
    Ascher-Svanum H; Nyhuis AW; Stauffer V; Kinon BJ; Faries DE; Phillips GA; Schuh K; Awad AG; Keefe R; Naber D
    Curr Med Res Opin; 2010 Oct; 26(10):2403-10. PubMed ID: 20812791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a clinician questionnaire and patient interview to assess reasons for antipsychotic discontinuation.
    Matza LS; Phillips GA; Revicki DA; Ascher-Svanum H; Kaiser D; Stauffer V; Shorr JM; Kinon BJ
    Psychiatry Res; 2011 Oct; 189(3):463-8. PubMed ID: 21684017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians.
    Chen J; Ascher-Svanum H; Nyhuis AW; Case MG; Phillips GA; Schuh KJ; Hoffmann VP
    Patient Prefer Adherence; 2011; 5():547-54. PubMed ID: 22114469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-reported reasons for discontinuation or continuation of antipsychotic medication in individuals with first-episode schizophrenia.
    Stürup AE; Hjorthøj C; Jensen HD; Melau M; Davy JW; Nordentoft M; Albert N
    Early Interv Psychiatry; 2023 Oct; 17(10):974-983. PubMed ID: 36693651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and psychometric evaluation of a clinical global impression for schizoaffective disorder scale.
    Allen MH; Daniel DG; Revicki DA; Canuso CM; Turkoz I; Fu DJ; Alphs L; Ishak KJ; Bartko JJ; Lindenmayer JP
    Innov Clin Neurosci; 2012 Jan; 9(1):15-24. PubMed ID: 22347687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder.
    Dunayevich E; Ascher-Svanum H; Zhao F; Jacobson JG; Phillips GA; Dellva MA; Green AI
    J Clin Psychiatry; 2007 Aug; 68(8):1163-71. PubMed ID: 17854239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder.
    Byerly MJ; Nakonezny PA; Rush AJ
    Schizophr Res; 2008 Mar; 100(1-3):60-9. PubMed ID: 18255269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
    Kerwin R; Millet B; Herman E; Banki CM; Lublin H; Pans M; Hanssens L; L'Italien G; McQuade RD; Beuzen JN
    Eur Psychiatry; 2007 Oct; 22(7):433-43. PubMed ID: 17555947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient perspectives on antipsychotic treatments and their association with clinical outcomes.
    Liu-Seifert H; Osuntokun OO; Godfrey JL; Feldman PD
    Patient Prefer Adherence; 2010 Oct; 4():369-77. PubMed ID: 21049089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between previous high-dose antipsychotic therapy and brexpiprazole discontinuation after the initiation of brexpiprazole in patients with schizophrenia or schizoaffective disorder.
    Yoshimura Y; Shimizu H; Yamashita R; Washida K; Takeda T; Aoki S
    Int Clin Psychopharmacol; 2020 Mar; 35(2):98-104. PubMed ID: 31743231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rating scale to inform successful discontinuation of antipsychotics and antidepressants.
    Lincoln TM; Sommer D; Könemund M; Schlier B
    Psychiatry Res; 2021 Apr; 298():113768. PubMed ID: 33601071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preliminary examination of the validity and reliability of a new brief rating scale for symptom domains of psychosis: Brief Evaluation of Psychosis Symptom Domains (BE-PSD).
    Takeuchi H; Fervaha G; Lee J; Agid O; Remington G
    J Psychiatr Res; 2016 Sep; 80():87-92. PubMed ID: 27318892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
    Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST).
    Landolt K; Rössler W; Ajdacic-Gross V; Derks EM; Libiger J; Kahn RS; Fleischhacker WW;
    Schizophr Res; 2016 Apr; 172(1-3):145-51. PubMed ID: 26922655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial.
    Weiden PJ
    J Clin Psychiatry; 2007; 68 Suppl 1():12-9. PubMed ID: 17286523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.